Os Therapies Inc. (OSTX)
AMEX AMEX Primary Summary
OSTX Chart
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
On Friday, OS Therapies, Inc. (NYSE-A: OSTX) entered into agreements for the commercial manufacture of OST-HER2.
OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy
OSTX's OST-HER2 immunotherapy is in a fully enrolled phase 2b trial for osteosarcoma, which had an updated readout in mid-January 2025. Financially, OSTX has $7.9 million in cash, with recent funding providing a runway until 2026, but remains poorly capitalized and reliant on near-term news. Strengths include a mid-stage product for an unmet need, but risks involve past failures of Listeria-based immunotherapies and uncertain funding prospects.
OSTX CEO: "We Have a Lot of Milestones Coming" in Tumor Research
Paul Romness, CEO of OS Therapies (OSTX), joins Nicole Petallides at the NYSE after the company recently completed a critical phase of its Osteosarcoma research. As OS Therapies readies to send its data to the FDA, Paul discusses the similarities of the disease between humans and dogs and looks ahead to researching other solid tumors.
Os Therapies Inc. Dividends
Os Therapies Inc. Earnings
| 16 May 2025 Date | | - Cons. EPS | - EPS |
| 15 Nov 2024 Date | | - Cons. EPS | - EPS |
| 16 May 2025 Date | | - Cons. EPS | - EPS |
| 15 Nov 2024 Date | | - Cons. EPS | - EPS |
Os Therapies Inc. (OSTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Os Therapies Inc. ever had a stock split?
Os Therapies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Paul A. Romness M.P.H. CEO | AMEX Exchange | US68764Y2072 ISIN |
| United States Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
OS Therapies Incorporated stands as a clinical stage biopharmaceutical company committed to the advancement of treatments for osteosarcoma and other solid tumors. The company is actively engaged in the identification, development, and commercialization phases of novel treatments. With its foundation laid in 2018 and headquartered in Rockville, Maryland, OS Therapies Incorporated has made significant strides towards offering innovative solutions in the fight against cancer.
Products and Services
- OST-HER2:
An off-the-shelf immunotherapy candidate developed by OS Therapies Incorporated, OST-HER2 represents a pivotal development in the landscape of cancer treatment. Designed to harness the body's immune system to fight cancer, this product exemplifies the company's commitment to innovative cancer treatment paradigms.
- OST-TDC:
A next-generation tunable antibody-drug conjugate (ADC), OST-TDC features a state-of-the-art plug-and-play platform with tunable pH-sensitive silicone linkers. This technology allows for the precise targeting and delivery of cancer therapeutics, showcasing OS Therapies Incorporated's forefront position in advancing ADC technologies for cancer treatment.
Contact Information
